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Abstract
Introduction: Older adults experiencing subjective cogni-
tive decline (SCD) have a heightened risk of developing de-
mentia and frequently experience subclinical anxiety, which 
is itself associated with dementia risk. Objective: To under-
stand whether subclinical anxiety symptoms in SCD can be 
reduced through behavioral interventions. Methods: SCD-
Well is a randomized controlled trial designed to determine 
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whether an 8-week mindfulness-based intervention (caring 
mindfulness-based approach for seniors; CMBAS) is superior 
to a structurally matched health self-management program 
(HSMP) in reducing subclinical anxiety. Participants were re-
cruited from memory clinics at 4 European sites. The primary 
outcome was change in anxiety symptoms (trait subscale of 
the State-Trait Anxiety Inventory; trait-STAI) from pre- to 
postintervention. Secondary outcomes included a change in 
state anxiety and depression symptoms postintervention 
and 6 months postrandomization (follow-up). Results: One 
hundred forty-seven participants (mean [SD] age: 72.7 [6.9] 
years; 64.6% women; CMBAS, n = 73; HSMP, n = 74) were in-
cluded in the intention-to-treat analysis. There was no differ-
ence in trait-STAI between groups postintervention (adjust-
ed change difference: –1.25 points; 95% CI –4.76 to 2.25) or 
at follow-up (adjusted change difference: –0.43 points; 95% 
CI –2.92 to 2.07). Trait-STAI decreased postintervention in 
both groups (CMBAS: –3.43 points; 95% CI –5.27 to –1.59; 
HSMP: –2.29 points; 95% CI –4.14 to –0.44) and reductions 
were maintained at follow-up. No between-group differenc-
es were observed for change in state anxiety or depression 
symptoms. Conclusions: A time-limited mindfulness inter-
vention is not superior to health self-management in reduc-
ing subclinical anxiety symptoms in SCD. The sustained re-
duction observed across both groups suggests that subclin-
ical anxiety symptoms in SCD are modifiable. ClinicalTrials.
gov identifier: NCT03005652. © 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Individuals experiencing subjective cognitive decline 
(SCD), even without objective impairment, are at an in-
creased risk of developing dementia [1]. As outlined in 
the SCD-I framework [2], this risk is further elevated in 
people aged 60+ years who express concern about their 
memory and who seek professional help [3, 4]. These in-
dividuals frequently experience subclinical symptoms of 
anxiety, and evidence suggests that anxiety itself, even if 
subclinical, is associated with an increased risk of demen-
tia [5, 6]. SCD and anxiety symptoms may therefore pose 
a compounded risk of dementia. Yet, while there are es-
tablished interventions for anxiety disorders in old age, 
few attempts have been made to specifically address sub-
clinical levels of anxiety in groups at risk for dementia. 
Introducing an intervention that addresses this issue 
would not only benefit the mental health of people with 
SCD but could also potentially reduce the risk of demen-
tia.
In terms of psychological mechanisms, there is an in-
dication that concern about loss of cognitive function 
contributes to the elevated anxiety seen in individuals 
with SCD [7], and anxiety in turn increases alertness for 
cognitive failures [8, 9]. Mindfulness-based interven-
tions (MBI) may be particularly suited to address this 
dynamic. By teaching individuals to relate to their pres-
ent moment experience in a nonjudgemental and accep-
tant manner, MBI could help people with SCD to recog-
nize and disengage from worry processes and respond to 
cognitive failures with more acceptance, which may thus 
reduce anxiety. While mindfulness-based research in 
older adults is still in its infancy [10–12], there is consid-
erable evidence that MBI can reduce anxiety in a number 
of populations [13, 14]. In order to investigate the spe-
cific benefits that such an approach might offer, com-
parison against an active control is advisable as MBI con-
tain a number of nonspecific elements, such as social in-
teraction, education, and the provision of treatment 
expectancies.
Strategies to support brain health have recently been 
recommended for individuals with SCD. These include 
physical exercise, a healthy diet, and control of preexist-
ing conditions [3]. Therefore, a group-based health self-
management program (HSMP) was deemed an appropri-
ate comparison condition, as it might also benefit people 
with SCD. HSMPs assist individuals to identify problems, 
make decisions, and take actions to find solutions. The 
goal is to promote self-efficacy by providing individuals 
with skills to live an active and healthy life [15]. With re-
gard to concerns about loss of function experienced in 
SCD, empowering individuals to maintain function may 
reduce anxiety through mechanisms of action more distal 
to those assumed for MBI.
The SCD-Well randomized clinical trial sought to ex-
amine whether an MBI specially adapted for older adults 
with SCD, i.e., a caring mindfulness-based approach for 
seniors (CMBAS), reduces subclinical symptoms of anxi-
ety from pre- to postintervention (primary outcome) 
compared to a structurally matched HSMP and whether 
any reduction in symptoms is maintained at the 6-month 
follow-up (secondary outcome). We also present here re-
sults on the main secondary psychiatric outcomes (state 
anxiety and depression symptoms) and moderator analy-
ses are shown in the online supplementary material (see 
www.karger.com/doi/10.1159/000515669 for all online 
suppl. material).
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Detailed information about the methodology, including sites, 
eligibility criteria, interventions, and assessments, is provided in 
the trial protocol [16].
Study Design
SCD-Well is a multi-center, observer-blind, randomized, con-
trolled superiority trial with 2 intervention arms, i.e., CMBAS and 
HSMP. The trial included 8 weeks of intervention and a follow-up 
24 weeks after the intervention (a total of 6 months). The interven-
tion took place in group settings at 4 sites, and randomization was 
performed with a 1:1 allocation, stratified by site. 
SCD-Well is registered on ClinicalTrials.gov (NCT03005652) 
and adheres to Consolidated Standards of Reporting Trials (CON-
SORT) of nonpharmacologic treatments guidelines [17] (online 
suppl. Table 1). 
Participants
Participants were recruited by research teams from medical fa-
cilities (i.e., memory clinics) at the 4 European sites where the tri-
al assessments and delivery of the interventions took place (Lon-
don, Cologne, Lyon, and Barcelona). Participants were either re-
ferred to a memory clinic by a physician or were self-referrals. For 
inclusion, participants must have met eligibility requirements de-
tailed in the paper of Marchant et al. [16], which include research 
criteria for SCD [2] (self-perceived cognitive decline and normal 
performance on standardized cognitive tests). These criteria re-
quire that participants be without a current clinical diagnosis of 
mild cognitive impairment or dementia, anxiety, depression, or 
other psychiatric disorder [2]. 
Procedures
Participants were recruited in 2 waves at each site. Briefly, par-
ticipants who fulfilled the eligibility criteria and provided written 
informed consent were invited to the baseline visit (V1) and then 
randomized to 1 of the 2 intervention conditions. Participants 
were then invited to a preclass meeting for their allocated interven-
tion, at which point the allocation was revealed to them. A postint-
ervention visit (V2) was conducted after the end of the interven-
tion, and a follow-up visit (V3) was held 6 months after random-
ization. 
Randomization and Masking
After 14–25 participants in a given site had completed V1 (in 
order to achieve intervention group sizes between 7 and 13 par-
ticipants), these participants were randomized by a member of the 
scientific team (but not the psychometrist) on the same day and in 
their order of inclusion via a centralized procedure implemented 
in the study electronic case report form. Randomization was per-
formed with a 1:1 allocation, permuted blocks of size 4 and 6, and 
stratified by site. 
All members of the research team, apart from trial managers, 
were blind to the participants’ intervention condition. This includ-
ed psychometrists administering and scoring the outcome mea-
sures. At the beginning of every interaction with psychometrists, 
participants were instructed not to disclose their intervention con-
dition. Seven instances of unblinding occurred (3 during an assess-
ment session), all as a result of participant disclosure of their as-
signed intervention condition. When this occurred a different psy-
chometrist, blinded to the participant’s intervention assignment, 
conducted the subsequent assessments.
Interventions
Caring Mindfulness-based Approach for Seniors
CMBAS followed the general format of a mindfulness-based 
stress reduction program, consisting of a preclass interview, 8 
weekly group-based sessions 2 h in duration, and a half day of 
meditation practice in the 6th week of the program. It was specifi-
cally tailored to the needs of older adults, building on modifica-
tions suggested by Zellner Keller et al. [18] together with a focus 
on compassion and loving-kindness meditation. The psychoedu-
cational components were customized for individuals with SCD to 
help them to more adaptively manage concerns about cognitive 
functioning and tendencies to worry. Participants were asked to 
engage in home practice for approximately an hour a day, 6 days a 
week, which consisted of formal guided meditations and informal 
practices aimed at helping to generalize mindfulness skills to daily 
life. 
HSMP Comparison Condition
An HSMP was selected to control for nonspecific factors and 
treatment expectancies, minimize potential drop-out rates, and 
harmonize the comparator treatment option across countries 
[19]. The HSMP followed the same format and structure as the 
CMBAS and was matched in administration, dosage, and dura-
tion; including a half day of review with a healthy lunch and a 
discussion in the 6th week of the program. This group-based 
program was based on a published manual for guidance on liv-
ing with chronic conditions [20] that has been previously adapt-
ed and validated in an SCD population [21]. Topics included 
management of sleep, stress, exercise, medicines and memory, 
communication, healthy eating, and planning for the future. 
Each week, participants were asked to create and implement “ac-
tion plans” to promote engagement in activities to improve 
health and well-being. 
Interventional Engagement
Attendance was taken at each intervention session. After the 
first session, participants completed a questionnaire to assess their 
perceptions of intervention credibility and expectations of deriv-
ing benefit [22]. Responses were used to gage the equivalency of 
treatment expectations in the 2 intervention conditions. 
Facilitators
Each site had 2 clinically trained facilitators. One facilitator, 
who had undergone formal training to match criteria of the good 
practice guidelines of the UK network of mindfulness-based 
teacher trainers (www.ukmindfulnessnetwork.co.uk), delivered 
the CMBAS intervention. The other facilitator, who had at least 
3 years’ experience leading group-based clinical programs and/
or psychoeducational interventions (e.g., a clinical psychologist 
or equivalent), led the health self-management intervention. Fa-
cilitators received the intervention manual, instructions, and 
training about their respective intervention prior to the start of 
the study, completed self-report checklists to monitor the fidel-
ity of treatment delivery after each class [23], and received ongo-
ing supervision to promote standardization of delivery across 
sites. 
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Outcomes
All outcomes were collected at V1, V2, and V3. The primary 
outcome, i.e.,. the mean change in subclinical symptoms of trait 
anxiety from V1 to V2, was measured using the trait subscale of 
the State-Trait Anxiety Inventory (trait-STAI; range 20–80) [24]. 
trait-STAI scores are representative of a person’s general level of 
anxiety, and they have a test-retest reliability of 0.88 [25]. Interven-
tion effects for secondary outcomes were assessed as change from 
V1 to V2 or from V1 to V3. Key secondary outcomes included 
trait-STAI change from V1 to V3, present moment anxiety symp-
toms assessed using the state subscale of the STAI (state-STAI; 
range 20–80), and depressive symptoms assessed using the Geriat-
ric Depression Scale (GDS; range 0–15) [26]. See the paper by 
Marchant et al. [16] for a detailed explanation of the change in 
primary outcome from state- to trait-STAI.
Statistical Analyses
Sample Size
As the trait-STAI has no absolute cut-off levels, the sample size 
was based on the effect size (i.e., the ratio between the expected 
interarm differences from the common SD). With a minimum ef-
fect size of 0.50 (indicated as a reasonable expectation from a me-
ta-analysis summarizing efficacy of meditation interventions for 
reducing anxiety symptoms) [13], 64 participants per arm (128 
total) were needed to demonstrate a significant difference in the 
primary endpoint (mean difference in the change of trait-STAI 
scores in each intervention arm from V1 to V2) in a t test with 80% 
power and a 2-sided type I error of 5%. A greater number of par-
ticipants was recruited in anticipation that a small proportion of 
volunteers (<10%) may have missing data on the primary endpoint 
(e.g., due to loss of follow-up).
Comparative Analyses
A statistical analysis plan was developed and validated by the 
Trial Steering Committee before database lock and analyses. 
All analyses were adjusted for recruitment site and baseline 
prognostic factors (median-centered age, sex, median-centered 
Mini Mental State Examination (MMSE), and median-centered 
baseline scores of outcome). HSMP was used as the reference 
group in all comparisons so that a negative (positive) mean differ-
ence in change between groups could be interpreted as a higher 
(lower) decrease in outcome score in CMBAS.
The primary outcome (change in trait-STAI from V1 to V2) 
was compared between groups using an adjusted linear regres-
sion model. This analysis was first conducted according to the 
intent to treat principle with a “missing = failure” strategy for 
handling missing data on the primary endpoint. A failure was 
defined as the maximum trait-STAI increase from V1 to V2 ob-
served across sites. One missing baseline data point in the 
CMBAS group was replaced by the median of the whole popula-
tion for the primary analysis. The standardized effect size (Co-
hen’s d) for within-group change was computed as the mean 
observed change divided by the baseline observed SD of the out-
come in each group. The standardized effect size for between-
group difference was computed as the mean adjusted between-
group difference divided by the baseline observed pooled SD of 
the outcome [27]. A reliable change index was calculated from 
observed values to determine the number of participants who 
reported clinically significant improvement or deterioration fol-
lowing intervention [28].
Several sensitivity analyses for missing data were performed, 
and an additional “minimum intervention” subanalysis was done 
that included only participants who attended at least 4 classes – the 
a priori determined adequate minimum dose – with primary end-
point data available. The sensitivity analyses conducted included: 
(1) maximum bias strategy comparing groups with missing data 
replaced by a failure in 1 group and by a success (maximum de-
crease in trait-STAI observed in the whole population) in the oth-
er, and vice versa; (2) “missing = failure” strategy using a site-spe-
cific failure value; and (3) mixed-effects linear regression model 
with a slope change occurring 49 days after the start of the inter-
vention (i.e., theoretical time of V2) with an interaction term be-
tween time and the intervention arm, assuming missing-at-ran-
dom data.
The potential moderating effect of baseline intrinsic or extrin-
sic factors on the primary outcome was evaluated by testing an 
interaction term in the linear regression model between the inter-
vention group and each factor separately. These factors included 
recruitment site, sex, baseline trait-STAI, neuroticism, proxy mea-
sures of intelligence quotient, subjective cognition, and lifestyle. 
See the online supplementary material for descriptions of consid-
ered moderators. Quantitative variables (all factors apart from re-
cruitment site and sex) were divided into quartiles, and quartile 1 
and quartile 3 were considered to present the moderating effect. 
For comparison of secondary endpoints, we used mixed-effects 
regression models incorporating all outcome measurements (V1, 
V2, and V3) and a slope change 49 days after the start of the inter-
vention (i.e., theoretical time of V2). Post hoc analyses tested 
whether the changes in trait-STAI, state-STAI, and GDS scores 
were significantly different from zero from V1 to V2 or from V1 
to V3 in each group. Analyses were performed using SAS® soft-
ware (version 9.3 or higher).
Results
Participant Flow and Baseline Characteristics
Recruitment took place from March 23, 2017, to Janu-
ary 25, 2018. Data collection was completed on Septem-
ber 18, 2018. Figure 1 shows the flow of participants 
through the study. A total of 147 participants (mean [SD] 
age 72.7 [6.9] years; 95 females; 65%) were randomized. 
The CMBAS and HSMP intervention arms did not differ 
on demographic characteristics (Table 1) or baseline out-
come measures (Table 2). The median time between ran-
domization and the start of the intervention was 13 days 
(CMBAS: 13 days; HSMP: 15 days).
Intervention Fidelity
Checklists completed by facilitators indicated that 
87.5% of the sessions in the CMBAS condition were com-
plete, with facilitators missing no more than 1 element in 
the sessions and all of the missed elements reported being 
minor in nature (e.g., having missed brief closing prac-
tices or shortening of movement practices due to time 
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Assessed for eligibility:  (n = 168)
Included: (n = 153)
Randomized: (n = 147)
-Participant preincluded but not included (n = 11)
-Other (n = 4)
-Additional cognitive inclusion criteria
not met (n = 2)
-Refused to be randomized (n = 4)
-Performed intervention
-Did not perform intervention
Post-intervention follow-up completed
Post-intervention follow-up stopped
-Early termination (n = 3)
Post-intervention follow-up completed
Post-intervention follow-up stopped
-Early termination (n = 7)
-Post-intervention follow-up stopped (n = 3)
-Early termination (n = 1)
-Lost to follow-up/unable to contact (n = 1)
-Post-intervention follow-up stopped (n = 7)
-Early termination (n = 2)
Excluded from analysis
Analysis of the primary outcome
Excluded from analysis
Analysis of the primary outcome
-Performed intervention
-Did not perform intervention






















Female 95 (65) 47 (64) 48 (65)
Age, years 72.7±6.9 72.1±7.6 73.3±6.2
Education, years 13.6±3.6 13.9±3.8 13.4±3.4
Ethnicity
White 142 (97) 69 (94) 73 (99)
Recruitment site
London, UK 28 (19) 14 (19) 14 (19)
Lyon, France 40 (27) 20 (27) 20 (27)
Cologne, Germany 39 (26) 19 (26) 20 (27)
Barcelona, Spain 40 (27) 20 (27) 20 (27)
Employment
Retired 123 (85)a 58 (82)b 65 (88)
MMSE 28.8±1.1 28.7±1.2 28.9±1.0
Data are presented as means ± SD or numbers (%). a n = 145. b n = 71.
Table 1. Clinical and demographic 
characteristics of the intention-to-treat 
sample
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constraints). In the HSMP condition, checklists indicated 
that therapists covered the main steps of the standard ses-
sion sequence without exception.
Intervention Engagement
No significant differences were observed between the 
CMBAS and HSMP arms on participant ratings (n = 143) 
of credibility (5.9 [SD 2.2] vs. 5.3 [SD 1.9]) or expectancy 
(4.5 [SD 1.9] vs. 4.1 [SD 1.8]). One hundred twenty-one 
(85%) participants attended 4 or more sessions (CMBAS: 
82%; HSMP: 87%), the requirement for the minimum in-
tervention analysis. Participants had an average atten-
dance of 6.7 (SD 2.7) out of a maximum of 9 sessions 
(CMBAS = 6.7 [SD 2.8], HSMP = 6.8 [SD 2.7]). No differ-
ence was observed between intervention arms in the 
number of sessions attended (p = 0.95). One hundred 
Table 2. Observed values for all outcomes
Trait-STAI State-STAI GDS
CMBAS HSMP CMBAS HSMP CMBAS HSMP
n mean (SD) n mean (SD) n mean (SD) n mean (SD) n mean (SD) n mean (SD)
V1 72 40.7 (10.5) 74 39.1 (9.4) 73 33.6 (9.8) 74 31.5 (8.4) 73 3.1 (2.5) 74 2.0 (2.0)
V2 68 37.0 (9.8) 66 36.2 (9.1) 68 31.5 (8.8) 66 30.4 (8.3) 68 2.7 (2.9) 66 2.1 (2.2)
V3 68 37.3 (10.4) 65 36.3 (9.8) 68 32.8 (10.2) 65 29.7 (9.1) 68 2.6 (2.8) 64 2.0 (1.9)
Change from V1 to V2 67 –3.3 (7.5) 66 –2.4 (6.7) 68 –2.1 (9.9) 66 –0.9 (8.1) 68 –0.3 (2.0) 66 0.2 (1.9)
Change from V1 to V3 67 –3.0 (8.3) 65 –2.5 (7.9) 68 –0.6 (10.9) 65 –1.4 (8.5) 68 –0.4 (2.0) 64 0.1 (1.0)
Table 3. Results from the primary outcome and secondary outcomes
Primary 
outcome
Estimated changea Between-group 
difference in 
changea 
              p value 
CMBAS (n = 73) HSMP (n = 74)
Trait-STAI
V1 to V2 –1.02 (–3.54 to 1.50) 0.23 (–2.29 to 2.76) –1.25 (–4.76 to 2.25) 0.48
Secondary out-
comes
Estimated change Between-group 
difference in 
change 
              p value
CMBAS (n = 73) HSMP (n = 74)
Trait-STAI
V1 to V3 –2.92 (–4.67 to –1.17) –2.49 (–4.27 to –1.17) –0.43 (–2.92 to 2.07) 0.74
State-STAI
V1 to V2 –2.47 (–4.74 to –0.21) –0.88 (–3.16 to 1.40) –1.60 (–4.81 to 1.62) 0.33
V1 to V3 –0.76 (–2.88 to 1.36) –1.31 (–3.48 to 0.85) 0.55 (–2.48 to 3.59) 0.72
GDS
V1 to V2 –0.23 (–0.71 to 0.26) 0.20 (–0.29 to 0.69) –0.43 (–1.11 to 0.26) 0.22
V1 to V3 –0.34 (–0.80 to 0.12) 0.15 (–0.32 to 0.62) –0.49 (–1.14 to 0.17) 0.14
Values are presented as means (95% CI). All analyses are adjusted for: recruitment site, median-centered age, 
sex, median-centered MMSE, and median-centered baseline scores of outcome. a For Trait-STAI change between 
V1 and V2 (primary outcome), estimates and p values come from the linear regression model with missing = 
failure analysis, and for Trait-STAI change between V1 and V3, State-STAI, and GDS (secondary outcomes), 
estimates come from the mixed effect regression analysis.
Behavioral Interventions to Reduce 
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twenty-five (85%) participants completed at least 1 home-
work practice (CMBAS = 63 [85%]; HSMP = 63 [85%]). 
Fifty-six percent (75 out of 133) of the participants who 
returned for V3 reported that they continued practice 
during the follow-up period, i.e., 59% (40 out of 68) in 
CMBAS and 54% (35 out of 65) in health self-manage-
ment (p = 0.6). The median time between the start of the 
group-based intervention and V2 was 65 days (CMBAS: 
66 days; HSMP: 62 days), and between the start of the 
group-based intervention and V3 it was 174 days (CMBAS 
and HSMP: 174 days). 
Primary Outcome
The mean observed change in trait-STAI from V1 to 
V2 was –3.3 (SD 7.5) points (Cohen’s d = 0.31) in CMBAS 
and –2.4 (SD 6.7) points (Cohen’s d = 0.26) in HSMP 
(Table 2). There was no significant difference between 
groups (mean adjusted difference in change: –1.25; 95% 
CI –4.76 to 2.25, p = 0.48; Cohen’s d = 0.13; Table 3). Sen-
sitivity analyses supported these findings, as did the min-
imum intervention analysis (–0.39; 95% CI –2.88 to 2.09, 
p = 0.75; online suppl. Table 2). No significant moderat-
ing effect was identified for the considered baseline char-
acteristics (online suppl. material).
Secondary Outcomes
The mean adjusted difference in change in trait-STAI 
from V1 to V3 between intervention arms was not sig-
nificant (–0.43; 95% CI –2.92 to 2.07, p = 0.74; Cohen’s 
d = 0.04; Table 3). Neither the mean adjusted difference 
in change on the state-STAI from V1 to V2 (–1.60; 95% 
CI –4.81 to 1.62, p = 0.33; Cohen’s d = 0.18) nor that from 
V1 to V3 (0.55; 95% CI –2.48 to 3.59, p = 0.72; Cohen’s 
d = 0.06; Table 3) was significant. Regarding the GDS, the 
mean adjusted differences in change from V1 to V2 
(–0.43; 95% CI –1.11 to 0.26, p = 0.22; Cohen’s d = 0.19) 
and from V1 to V3 (–0.49; 95% CI –1.14 to 0.17, p = 0.14; 
Cohen’s d = 0.22; Table 3) were also not significant.
Post hoc Analyses
The change in trait-STAI was significantly different 
from zero in both intervention arms from V1 to V3 
(CMBAS: –2.92; 95% CI –4.67 to –1.17, p = 0.001; HSMP: 
–2.49; 95% CI –4.27 to –0.72, p = 0.006). This decrease 
was mainly observed from V1 to V2 (CMBAS: –3.43; 95% 
CI –5.27 to –1.59, p = 0.0003; HSMP: –2.29; 95% CI –4.14 
to –0.44, p = 0.02) and no change was observed from V2 
to V3 (CMBAS: 0.51; 95% CI –0.57 to 1.59, p = 0.35; 
HSMP: –0.20; 95% CI –1.28 to 0.88, p = 0.71; Fig.  2). 
Twenty-one participants (16%) reported a clinically sig-
nificant improvement in trait-STAI from V1 to V2 
(CMBAS: n = 11; HSMP: n = 10). 
Change was not significantly different from zero in ei-
ther intervention arm from V1 to V3 in state-STAI scores 
(CMBAS: –0.76; 95% CI –2.88 to 1.36, p = 0.48; HSMP: 
–1.31; 95% CI –3.48 to 0.85, p = 0.23) or GDS scores 
(CMBAS: –0.34; 95% CI –0.8 to 0.12, p = 0.15; HSMP: 
0.15; 95% CI –0.32 to 0.62, p = 0.53). However, the change 
in state-STAI was significantly different from zero in the 
CMBAS arm from V1 to V2 (–2.47; 95% CI –4.74 to 
–0.21, p = 0.03). No other changes from V1 to V2 were 
significantly different from zero. 
Deterioration and Adverse Events
Forty-four (33%) of the 133 participants who complet-
ed the primary outcome measure at both time points 
showed an increase (deterioration) in trait-STAI from V1 
to V2. There was no difference in deterioration between 
groups (CMBAS: n = 22; 33%; HSMP: n = 22; 33%), and 
only 2 participants (1.5%) reported a clinically significant 
deterioration. Twenty-five adverse events were recorded 
in the trial (CMBAS: 18; HSMP: 7), and 5 of them were 
considered serious adverse events (CMBAS: 4; HSMP: 1; 
online suppl. Table 3). None in either condition was 































Fig. 2. Evolution of average trait-STAI scores from baseline (V1) 
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Discussion
In this large, multinational clinical trial of older adults 
with SCD an 8-week CMBAS intervention was not supe-
rior to an HSMP at reducing subclinical anxiety symp-
toms. Intervention engagement and potential iatrogenic 
effects were equivalent in both conditions [29], and no 
study-related adverse events were reported. 
Despite the extant literature reporting beneficial ef-
fects of MBI on both clinical and subclinical symptoms of 
anxiety [13, 14], we observed no substantial difference in 
subclinical anxiety symptom reduction between inter-
vention conditions. This finding further contrasts with 
that of a previously published trial reporting a differential 
benefit of an MBI compared with an HSMP on symptoms 
of anxiety in participants with cognitive complaints [21]. 
Participants in the previous trial had a current diagnosis 
of depression and/or anxiety, whereas this was an exclu-
sion for SCD-Well. While participants in our trial did 
show elevated baseline anxiety symptoms, in line with ob-
servational studies of SCD [30], it may be that clinically 
significant anxiety is needed for a differential effect of 
MBI to emerge in this population. 
In the present study, participants in both intervention 
groups showed a reduction in trait anxiety at the end of 
the intervention that was maintained 6 months later. This 
reduction left participants well within the normal range 
of anxiety symptoms [31] and suggests that anxiety levels 
in individuals with SCD are malleable. However, because 
the trial did not include a passive control, we were unable 
to directly examine whether changes in anxiety symp-
toms were specifically due to the interventions. In an ef-
fort to answer this question, we extracted the average 
trait-STAI change from passive control conditions used 
in 8-week MBI studies across a range of populations that 
were included in earlier reviews [13, 14] (see online suppl. 
Table 4 for references). The average reported change 
from those 6 studies was 0.3 (compared with –3.3 in 
CMBAS and –2.4 in HSMP reported here), indicating 
that anxiety was relatively stable over time in a passive 
condition. When studies were restricted to those with an 
average participant age of 50 years or older, trait-STAI 
increased by 2.2 on average over 8 weeks. While only in-
dicative, and not confirmatory, these data support the in-
terpretation that both interventions employed in SCD-
Well led to the reduction of anxiety symptoms. 
A sustained decrease in state symptoms of anxiety was 
not observed in either intervention condition. State anxi-
ety describes symptoms experienced in the present mo-
ment, while trait anxiety describes symptoms generally 
experienced over time. The observation of a sustained re-
duction of trait but not state anxiety indicates that par-
ticipants experienced an enduring shift in subclinical 
anxiety levels rather than acute responses to a stressor 
(e.g., clinical test environment). Despite MBI having been 
shown to effectively reduce depressive symptoms [14], we 
found no effect in SCD-Well. As depressive symptoms 
were already near floor at baseline, there was little room 
for improvements to be observed. As with trait anxiety 
symptoms, a positive effect on depressive symptoms 
might be anticipated in future trials that include older 
adults with higher or clinically significant levels of de-
pression. 
The SCD-Well trial has several strengths. It is the first 
multicountry intervention study in SCD, which increases 
the generalizability of the findings. In line with method-
ological recommendations for randomized controlled 
trials of psychological interventions [32], we used a man-
ualized intervention with a clinically relevant comparison 
condition that incorporated the same amount of facilita-
tor contact time as the experimental condition, described 
the “treatment ingredients” of both interventions [see 
16], included a 6-month follow-up assessment, and re-
ported the number of participants who deteriorated (i.e., 
reported an increase in anxiety symptoms) after treat-
ment. Compared to previous mindfulness trials in SCD 
[21, 33, 34], our trial had a larger sample size, comprising 
older adults recruited solely from memory clinics. We fol-
lowed research recommendations [35] to homogenize 
our sample by using a standardized definition of SCD [2, 
36], by using predefined criteria to exclude MCI [16, 37], 
and by excluding participants with psychiatric or neuro-
degenerative disorders. 
This study does, however, have limitations. First, there 
are methodological constraints. Most importantly, no 
passive control was included so we were unable to ascer-
tain whether the reduction in anxiety symptoms observed 
in both conditions was specifically due to intervention. 
Despite the statistically significant reductions in trait-
STAI observed in both conditions, clinically significant 
reductions were limited. Recent meta-analytic evidence 
suggests that the trait-STAI captures negative affectivity 
more than anxiety [38], thus offering the possibility that 
the negative results observed here may be due to measure-
ment insensitivity. We are further unable to explain why 
no difference was observed between conditions. For ex-
ample, intervention duration (e.g., most drug trials are 
significantly longer), the strength of the comparator con-
dition [19], or the limited range of anxiety symptoms due 
to exclusion of anxiety disorders could all have made the 
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detection of intervention effects more difficult. Second, 
the causes of SCD are heterogeneous, and despite making 
attempts to homogenize the sample, different underlying 
etiologies of SCD likely remained and could have affected 
the results. Third, the follow-up was relatively short. Po-
tential long-term effects on anxiety symptoms or demen-
tia incidence could not be assessed. Future analyses from 
SCD-Well, and its sister trial Age-Well [39], will further 
characterize the possible specificities of these interven-
tions on cognition, aging, and health.
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